Fulcrum Therapeutics Inc

NASDAQ:FULC 4:00:00 PM EDT

7.44

+0.19 (+2.62%)

4:49:35 PM EDT: $7.29 -0.15 (-2.02%)

Market Cap (Intraday)	460.79M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.42 Million
Adjusted EPS	-$0.44

See more estimates

10-Day MA	$7.51
50-Day MA	$9.43
200-Day MA	$6.11

See more pivots

Fulcrum Therapeutics Inc Stock, NASDAQ:FULC

26 Landsdowne Street, Cambridge, Massachusetts 02139

United States of America

Phone: +1.617.651.8851

Number of Employees: 76

http://www.fulcrumtx.com

Description

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.